Albireo Pharma (FRA:BDQM) Accounts Payable & Accrued Expense : €32.64 Mil (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Accounts Payable & Accrued Expense?

Albireo Pharma's quarterly accounts payable & accrued expense increased from Mar. 2022 (€24.95 Mil) to Jun. 2022 (€26.89 Mil) and increased from Jun. 2022 (€26.89 Mil) to Sep. 2022 (€32.64 Mil).

Albireo Pharma's annual accounts payable & accrued expense increased from Dec. 2019 (€16.44 Mil) to Dec. 2020 (€20.00 Mil) and increased from Dec. 2020 (€20.00 Mil) to Dec. 2021 (€37.58 Mil).

Albireo Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Albireo Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Accounts Payable & Accrued Expense Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

6.17

11.00

16.44

20.00

37.58

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															23.89	37.58	24.95	26.89	32.64

Albireo Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines